OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Endocrinology is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Novel inflammatory biomarkers in thyroid eye disease	454
Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe	184
Letter to the Editor from Piazzola and Castinetti: “Bilateral inferior petrosal sinus sampling with human CRH stimulation in ACTH-dependent Cushing’s syndrome: results from a retrospective multicenter	126
Reply to the letter to the editor from Piazzola and Castinetti: “Bilateral inferior petrosal sinus sampling with human CRH stimulation in ACTH dependent Cushing's syndrome: results from a retrospectiv	107
More than meets the eye: predicting adrenocortical carcinoma outcomes with pathomics	97
How to manage Cushing's disease after failed primary pituitary surgery	83
Glycaemic status, insulin resistance, and risk of infection-related mortality: a cohort study	67
Response to the letter of Hoermann and colleagues	59
Evaluation of a new transition organization for young adults with endocrine or metabolic diseases	56
Broad-spectrum XX and XY gonadal dysgenesis in patients with a homozygous L193S variant in PPP2R3C	55
Erratum to: “Adenylate cyclase stimulation and [3H]thymidine incorporation in human thyroid tissues and thyrocyte cultures: The effect of IgG preparation from patients with different thyroid disorders	54
Association of sleep and circadian patterns and genetic risk with incident type 2 diabetes: a large prospective population-based cohort study	53
Plasma glycated CD59 predicts postpartum glucose intolerance after gestational diabetes	51
Inflammatory biomarkers in the evaluation of pediatric endogenous Cushing syndrome	49
Psychopathological characteristics in patients with arginine vasopressin deficiency (central diabetes insipidus) and primary polydipsia compared to healthy controls	49
Extensive expertise in endocrinology: advances in the management of glucocorticoid-induced osteoporosis	46
MECHANISMS IN ENDOCRINOLOGY: The gut–brain axis: regulating energy balance independent of food intake	42
Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience	42
High prevalence of variants in skeletal dysplasia associated genes in individuals with short stature and minor skeletal anomalies	41
Biallelic POC1A variants cause syndromic severe insulin resistance with muscle cramps	41
Familial hyperaldosteronism: an European Reference Network on Rare Endocrine Conditions clinical practice guideline	41
Corticosteroid rhythms in hypoparathyroid patients	40
Evaluation and follow-up of patients diagnosed with hypophysitis: a cohort study	40
Surgical versus medical treatment for unilateral primary aldosteronism: an alternative to a randomized controlled trial	37
Compression of the optic chiasm is associated with reduced photoentrainment of the central biological clock	37

Overexpression of miR-7977 in CD4+ T cells is associated with multiplex autoimmunity in patients with Addison’s disease	35
Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis	35
Mineralocorticoid receptor antagonists for primary aldosteronism—appropriate or not?	35
Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring	34
Risk of dementia and psychiatric or sleep disorders after diagnosis of adrenal adenomas: a population-based cohort study	33
Isthmus topography is a risk factor for persistent disease in patients with differentiated thyroid cancer	33
18-year change in serum intact fibroblast growth factor 23 from midlife to late life and risk of mortality: the ARIC Study	32
Intramuscular fatty infiltration and physical function in controlled acromegaly	32
Durable biochemical response and safety with oral octreotide capsules in acromegaly	32